Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Primary immunodeficiencies: novel genes and unusual presentations

Luigi D. Notarangelo, Gulbu Uzel, V. Koneti Rao

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 443–448.

https://doi.org/10.1182/hematology.2019000051

Published: 2019

Journal Articles

Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome

Jibran Durrani, Jaroslaw P. Maciejewski

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 97–104.

https://doi.org/10.1182/hematology.2019000019

Published: 2019

Journal Articles

Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease

David C. Fajgenbaum

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 318–325.

https://doi.org/10.1182/asheducation-2018.1.318

Published: 2018

Journal Articles

Old and new tools in the clinical diagnosis of inherited bone marrow failure syndromes

Allison H. West, Jane E. Churpek

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 79–87.

https://doi.org/10.1182/asheducation-2017.1.79

Published: 2017

Journal Articles

Pediatric leukemia susceptibility disorders: manifestations and management

Lisa J. McReynolds, Sharon A. Savage

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 242–250.

https://doi.org/10.1182/asheducation-2017.1.242

Published: 2017

Journal Articles

New challenges in evaluating anemia in older persons in the era of molecular testing

David P. Steensma

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 67–73.

https://doi.org/10.1182/asheducation-2016.1.67

Published: 2016

Journal Articles

Nontransplant therapy for bone marrow failure

Danielle M. Townsley, Thomas Winkler

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 83–89.

https://doi.org/10.1182/asheducation-2016.1.83

Published: 2016

Journal Articles

Treatment of low-risk myelodysplastic syndromes

Valeria Santini

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 462–469.

https://doi.org/10.1182/asheducation-2016.1.462

Published: 2016

Journal Articles

Myelodysplastic and myeloproliferative disorders of childhood

Henrik Hasle

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 598–604.

https://doi.org/10.1182/asheducation-2016.1.598

Published: 2016

Journal Articles

The unique aspects of presentation and diagnosis of hemophagocytic lymphohistiocytosis in adults

Sarah Nikiforow, Nancy Berliner

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 183–189.

https://doi.org/10.1182/asheducation-2015.1.183

Published: 2015

Journal Articles

Reclassifying myelodysplastic syndromes: what's where in the new WHO and why

Daniel A. Arber, Robert P. Hasserjian

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 294–298.

https://doi.org/10.1182/asheducation-2015.1.294

Published: 2015

Journal Articles

The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP)

Luca Malcovati, Mario Cazzola

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 299–307.

https://doi.org/10.1182/asheducation-2015.1.299

Published: 2015

Journal Articles

Established and novel agents for myelodysplastic syndromes

Mikkael A. Sekeres, Aaron T. Gerds

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 82–89.

https://doi.org/10.1182/asheducation-2014.1.82

Published: 2014

Journal Articles

Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes

Yogen Saunthararajah

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 511–521.

https://doi.org/10.1182/asheducation-2013.1.511

Published: 2013

Journal Articles

Who benefits from allogeneic transplantation for myelodysplastic syndromes?: new insights

Uwe Platzbecker

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 522–528.

https://doi.org/10.1182/asheducation-2013.1.522

Published: 2013

Journal Articles

Management of the refractory aplastic anemia patient: what are the options?

Judith C. W. Marsh, Austin G. Kulasekararaj

Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 87–94.

https://doi.org/10.1182/asheducation-2013.1.87

Published: 2013

Journal Articles

Interpreting new molecular genetics in myelodysplastic syndromes

Omar Abdel-Wahab, Maria E. Figueroa

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 56–64.

https://doi.org/10.1182/asheducation.V2012.1.56.3798194

Published: 2012

Journal Articles

Low blood counts: immune mediated, idiopathic, or myelodysplasia

Peter Valent

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 485–491.

https://doi.org/10.1182/asheducation.V2012.1.485.3798522

Published: 2012

Journal Articles

Novel therapeutic strategies: hypomethylating agents and beyond

Valeria Santini

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 65–73.

https://doi.org/10.1182/asheducation.V2012.1.65.3806843

Published: 2012

Journal Articles

Classification of Childhood Aplastic Anemia and Myelodysplastic Syndrome

Charlotte M. Niemeyer, Irith Baumann

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 84–89.

https://doi.org/10.1182/asheducation-2011.1.84

Published: 2011

NARROW

Primary immunodeficiencies: novel genes and unusual presentations

Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome

Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease

Old and new tools in the clinical diagnosis of inherited bone marrow failure syndromes

Pediatric leukemia susceptibility disorders: manifestations and management

New challenges in evaluating anemia in older persons in the era of molecular testing

Nontransplant therapy for bone marrow failure

Treatment of low-risk myelodysplastic syndromes

Myelodysplastic and myeloproliferative disorders of childhood

The unique aspects of presentation and diagnosis of hemophagocytic lymphohistiocytosis in adults

Reclassifying myelodysplastic syndromes: what's where in the new WHO and why

The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP)

Established and novel agents for myelodysplastic syndromes

Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes

Who benefits from allogeneic transplantation for myelodysplastic syndromes?: new insights

Management of the refractory aplastic anemia patient: what are the options?

Interpreting new molecular genetics in myelodysplastic syndromes

Low blood counts: immune mediated, idiopathic, or myelodysplasia

Novel therapeutic strategies: hypomethylating agents and beyond

Classification of Childhood Aplastic Anemia and Myelodysplastic Syndrome

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only